| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 46.12% | Morgan Stanley | $17 → $16 | Maintains | Equal-Weight |
| 09/01/2023 | 91.78% | Roth MKM | → $21 | Reiterates | Buy → Buy |
| 08/31/2023 | 55.25% | Morgan Stanley | $18 → $17 | Maintains | Equal-Weight |
| 08/29/2023 | 91.78% | Roth MKM | → $21 | Reiterates | Buy → Buy |
| 07/27/2023 | 64.38% | Morgan Stanley | $18 → $18 | Reiterates | Equal-Weight → Equal-Weight |
| 05/04/2023 | 64.38% | Morgan Stanley | $19 → $18 | Maintains | Equal-Weight |
| 02/09/2023 | 73.52% | Morgan Stanley | $20 → $19 | Maintains | Equal-Weight |
| 12/21/2022 | 64.38% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 11/10/2022 | 82.65% | Morgan Stanley | $21 → $20 | Maintains | Equal-Weight |
| 09/16/2022 | 55.25% | Barclays | $22 → $17 | Maintains | Underweight |
| 08/26/2022 | 91.78% | Morgan Stanley | $23 → $21 | Maintains | Equal-Weight |
| 07/25/2022 | 100.91% | Barclays | → $22 | Downgrades | Equal-Weight → Underweight |
| 01/10/2022 | 110.05% | Barclays | → $23 | Upgrades | Underweight → Equal-Weight |
| 11/18/2021 | 110.05% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 07/07/2021 | 110.05% | Barclays | → $23 | Downgrades | Equal-Weight → Underweight |
| 05/13/2021 | 100.91% | Morgan Stanley | $19 → $22 | Maintains | Underweight |
| 05/08/2020 | 110.05% | Credit Suisse | $25 → $23 | Maintains | Neutral |
| 02/06/2020 | — | Gabelli & Co. | Downgrades | Buy → Hold | |
| 01/28/2020 | 110.05% | Barclays | → $23 | Upgrades | Underweight → Equal-Weight |
| 09/05/2019 | 91.78% | Morgan Stanley | $30 → $21 | Upgrades | Underweight → Equal-Weight |
| 08/29/2019 | 64.38% | B of A Securities | $29 → $18 | Reiterates | → Underperform |
| 08/29/2019 | 64.38% | Barclays | $25 → $18 | Maintains | Underweight |
| 08/28/2019 | 128.31% | Credit Suisse | $31 → $25 | Reiterates | → Neutral |
| 06/11/2019 | 128.31% | Barclays | → $25 | Initiates Coverage On | → Underweight |
| 05/09/2019 | — | Gabelli & Co. | Upgrades | Hold → Buy |
What is the target price for Phibro Animal Health (PAHC)?
The latest price target for Phibro Animal Health (NASDAQ: PAHC) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $16.00 expecting PAHC to rise to within 12 months (a possible 46.12% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Phibro Animal Health (PAHC)?
The latest analyst rating for Phibro Animal Health (NASDAQ: PAHC) was provided by Morgan Stanley, and Phibro Animal Health maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Phibro Animal Health (PAHC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Phibro Animal Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Phibro Animal Health was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Phibro Animal Health (PAHC) correct?
While ratings are subjective and will change, the latest Phibro Animal Health (PAHC) rating was a maintained with a price target of $17.00 to $16.00. The current price Phibro Animal Health (PAHC) is trading at is $10.95, which is out of the analyst's predicted range.